• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

    3.980 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 17
    Open 3.980
    Bid (Size) 3.600 (300)
    Ask (Size) 4.000 (300)
    Prev. Close 3.980
    Today's Range 3.980 - 3.980
    52wk Range 2.120 - 7.550
    Shares Outstanding 38,886,465
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -38.3%
    -38.3%
    1 Month
    +0.8%
    +0.8%
    3 Month
    -33.2%
    -33.2%
    6 Month
    -23.0%
    -23.0%
    1 Year
    +22.5%
    +22.5%

    More News

    Read More
    News headline image
    AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    AQST CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Aquestive Therapeutics Inc (NASDAQ:AQST) Reports Mixed Q4 2025 Results and Anaphylm Regulatory Update ↗
    Via Chartmill
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    AQST UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Rosen Law Firm Urges Aquestive Therapeutics, Inc. (NASDAQ: AQST) Stockholders to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    AQUESTIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    News headline image
    Aquestive (AQST) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Lawsuit
    News headline image
    Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?
    Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?
    The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market
    What is the current price of Aquestive Therapeutics, Inc. - Common Stock?
    The current price of Aquestive Therapeutics, Inc. - Common Stock is 3.980
    When was Aquestive Therapeutics, Inc. - Common Stock last traded?
    The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 03/20/26 04:00 PM ET
    What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?
    The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 154.77M
    How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?
    Aquestive Therapeutics, Inc. - Common Stock has 155M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.